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Lactobacillus plantarum LAB 12, a lactic acid bacteria (LAB) strain isolated 
from local fermented food, possess probiotic characteristics. In spite of 
their chemopreventive properties, the vulnerability of LAB 12 during 
gastrointestinal transit (pH and enzymatic action) and industrial processing 
(heat and storage) remains a major concern. This study addressed these issues 
by immobilising LAB 12, by means of microencapsulation, within alginate 
(Alg)-based polymeric matrix, with incorporation of xanthan gum (XG) 
and coated with Ch (Alg-XG-Ch), or pea protein isolate (PPi; Alg-PPi). The 
physicochemical properties of Alg-based microcapsules were characterised 
by means of Fourier transform infrared (FTIR), X-ray diffraction (XRD) 
and differential scanning calorimetry (DSC) analysis. Survivability of 
microencapsulated LAB 12 exposed to simulated gastrointestinal fluids 
(pH 1.8 and pH 6.8), high temperatures and various storage conditions 
(4/8-week storage at 4 and 25 °C) were assessed. Pelletisation study 
was conducted to evaluate the survivability of microencapsulated 
LAB 12 subjected to actual heat challenge in industrial processing. The 
microencapsulated LAB 12 was further assessed for their safety through 
acute and subchronic toxicity studies in vivo. The fate and release of 
LAB 12 from Alg-based microcapsules in different rodent gut sections were 
examined by means of confocal microscopy and qPCR respectively. The 
chemopreventive properties of microencapsulated LAB 12 were validated 
using an orthotopic mouse model. The Alg-XG-Ch microcapsules diameter 
(1299-1343 Lim) were relatively outsized (> 350 \xm), a feature which 
could adversely affect sensory properties resulting in inappropriate mouth 
feel and flavour. Alg-PPi microcapsules, on the other hand were presented 
with a smaller diameter range (157.7-189.5 Lim) and could be an ideal 
microencapsulation system for LAB 12. This was based on their excellent 
tolerance against simulated gastric juice (96.4% survivability, intense heat 
(80.2% survivability at 100 °C for 30 minutes), storage (>7 log CFU g-1 
after 8-week storage at 4 and 25 °C), pelletisation (89.4% survivability) 
and targeted release in simulated intestinal fluid (>9 log CFU g-1). The 
Alg-PPi LAB 12 microcapsules were used for all the susequent in vivo 
studies. For toxicity studies, no treatment (2.5 ><1010 CFU kg-1 BW) 
related adverse effects were observed in serum biochemistry and blood 
haematology. Histological sections of vital organs which included heart, 
kidney, lung, spleen, liver and gonads suggests that LAB 12 encapsulated 
in Alg-PPi were non-pathogenic and safe for consumption. As for the in 
vivo release study, the microcapsules were found intact in the stomach 
and LAB 12 were found to be present abundantly (>7 log CFU) only in the 
intestines. Also, orthotopic mouse model pre-fed with microencapsulated 
LAB 12 significantly (p < 0.05) reduced tumour volume (-98.87%) and 
weight (-89.27%) when compared to control. The chemopreventive effect 
could be possibly attributed to apoptosis and antiangiogenesis mediated. 
at least in part, through up-regulation of p53 (+32.50%) and caspase-3 
(+92.61%), and down-regulation of COX-2 (-63.96%), VEGF (-65.93%) 
and PECAM-1 (-62.72%). Altogether, this study strongly implied the 
possibility of having the LAB12-loaded Alg-PPi microcapsules safely 
incorporated into various food types and nutraceutical products upon 
succesful completion of clinical trials. 
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Malaysian public hospitals medicines procurement is one of the core 
elements in Malaysia National Medicines Policy (MNMP). Medicines 
procurement is one of the underlying policies that influence medicines 
accessibility, availability and affordability to public and Ministry of 
Health's healthcare institutions. Astute medicines allocation and planning 
strategy are imperative as competent medicines procurement management 
services in tandem with changes in the population, cost and usage will 
ensure competent of medicines supply. However, there are limitations in 
the identification of medicines' procurement indicators based on their 
costs of performances which may be affecting medicines procurement 
policy. This study aimed to determine medicines procurement indicators 
trending profiles and developing Medicines Procurement Indicators Tool. 
This study was conducted in two phases, Phase I and Phase II using panel 
data and cross-sectional study design respectively. Phase I is conducted 
to determine trending profiles of medicines procurement based on data of 
138 public hospitals in Malaysia from the year 2012-2014. The second 
phase of the study is to develop Medicines Procurement Indicators Tool. 
In Phase II, newly developed questionnaires were emailed to all respective 
pharmacists in 138 public hospitals in Malaysia. Questionnaires were 
validated and analysed using Pearson Chi-Square and Cochran's Q Test. 
In Phase I, the trending profiles for Special Medicines, URL and URUL 
recorded the highest purchase cost in 2012. While for RUL category, the 
highest cost purchase was in 2014. Medicines stock cycle recorded the 
highest value in 2012 while cost of medicines wastage and additional 
allocation received showed highest value in 2014. Types of products' 
trending profiles with the highest value recorded are Import Generics 
and Local Innovator purchasein 2014. Year 2012 recorded highest Local 
Generics purchase while Import Innovator showed highest value in 
2013. In Phase II of the study, Pearson Chi-Square test performed has 
found out that all categories under Special Medicines Indicator were 
associated with types of hospitals in Malaysia with p<0.05. For Type 
of Products Indicators, Local Generic,Import Innovator and Generic 
over Innovator showed association with types of hospitals. Cochran's Q 
test performed has found out that Generics over Innovator and Special 
Medicines namely Medicines Stock Cycle and Additional Medicines 
Allocation are significantly different based on years of measurement 
(p<0.05). Based on the statistical analysis done, components with 
significant data were constructed into Medicines Procurement Indicator 
Tool. In conclusion, based on medicines procurement indicators 
trending profiles shown, it has indicated the need for government to 
strategies and empowering current policy on medicines procurement by 
implementing the use of Medicines Procurement Indicator Tool. This 
measure will provide benefits to stakeholders via accurate information 
on tool implementation as well as reducing wastage and workload. 
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